176 related articles for article (PubMed ID: 22696210)
1. Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer.
Huang J; Li YM; Massague J; Sicheneder A; Vallera DA; Hall WA
J Neurooncol; 2012 Sep; 109(2):229-38. PubMed ID: 22696210
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of bispecific targeted immunotoxin DTATEGF against NSCLC brain metastatic tumor PC9-BrM3 cells].
Huang J; Li B; Li J; Liu D; Li Y; Hall WA; Yuan D
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Dec; 38(12):1217-22. PubMed ID: 24384958
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of antiangiogenic targeted immunotoxin DTAT and DTATEGF against glioblastoma multiforme.
Huang J; Yuan D; Liu D; Li J; Li Y; A Hall W; Li B
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Jan; 39(1):1-5. PubMed ID: 24473378
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain.
Oh S; Tsai AK; Ohlfest JR; Panoskaltsis-Mortari A; Vallera DA
J Neurosurg; 2011 Jun; 114(6):1662-71. PubMed ID: 21294620
[TBL] [Abstract][Full Text] [Related]
5. Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery.
Oh S; Ohlfest JR; Todhunter DA; Vallera VD; Hall WA; Chen H; Vallera DA
J Neurooncol; 2009 Dec; 95(3):331-342. PubMed ID: 19517064
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract][Full Text] [Related]
7. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT.
Vallera DA; Li C; Jin N; Panoskaltsis-Mortari A; Hall WA
J Natl Cancer Inst; 2002 Apr; 94(8):597-606. PubMed ID: 11959893
[TBL] [Abstract][Full Text] [Related]
8. Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model.
Stish BJ; Oh S; Vallera DA
J Neurooncol; 2008 Mar; 87(1):51-61. PubMed ID: 18084721
[TBL] [Abstract][Full Text] [Related]
9. Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.
Xiang Y; Li Q; Huang D; Tang X; Wang L; Shi Y; Zhang W; Yang T; Xiao C; Wang J
Exp Biol Med (Maywood); 2015 Feb; 240(2):160-8. PubMed ID: 25125500
[TBL] [Abstract][Full Text] [Related]
10. A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.
Tsai AK; Oh S; Chen H; Shu Y; Ohlfest JR; Vallera DA
J Neurooncol; 2011 Jun; 103(2):255-66. PubMed ID: 20830604
[TBL] [Abstract][Full Text] [Related]
11. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
Todhunter DA; Hall WA; Rustamzadeh E; Shu Y; Doumbia SO; Vallera DA
Protein Eng Des Sel; 2004 Feb; 17(2):157-64. PubMed ID: 15047912
[TBL] [Abstract][Full Text] [Related]
12. Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice.
Rustamzadeh E; Hall WA; Todhunter DA; Vallera VD; Low WC; Liu H; Panoskaltsis-Mortari A; Vallera DA
Int J Cancer; 2007 Jan; 120(2):411-9. PubMed ID: 17075792
[TBL] [Abstract][Full Text] [Related]
13. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
[TBL] [Abstract][Full Text] [Related]
14. Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.
Rustamzadeh E; Li C; Doumbia S; Hall WA; Vallera DA
J Neurooncol; 2003 Oct; 65(1):63-75. PubMed ID: 14649886
[TBL] [Abstract][Full Text] [Related]
15. Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model.
Vallera DA; Stish BJ; Shu Y; Chen H; Saluja A; Buchsbaum DJ; Vickers SM
Gut; 2008 May; 57(5):634-41. PubMed ID: 18222985
[TBL] [Abstract][Full Text] [Related]
16. A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer.
Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
Clin Cancer Res; 2007 Nov; 13(21):6486-93. PubMed ID: 17975161
[TBL] [Abstract][Full Text] [Related]
17. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer.
Yang X; Kessler E; Su LJ; Thorburn A; Frankel AE; Li Y; La Rosa FG; Shen J; Li CY; Varella-Garcia M; Glodé LM; Flaig TW
Clin Cancer Res; 2013 Jan; 19(1):148-57. PubMed ID: 23172881
[TBL] [Abstract][Full Text] [Related]
18. Convection-enhanced delivery of sorafenib and suppression of tumor progression in a murine model of brain melanoma through the inhibition of signal transducer and activator of transcription 3.
Zou Z; Yin Y; Lin J; Hsu LC; Brandon VL; Yang F; Jove R; Jandial R; Li G; Chen MY
J Neurosurg; 2016 May; 124(5):1310-8. PubMed ID: 26544779
[TBL] [Abstract][Full Text] [Related]
19. Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice.
Li C; Hall WA; Jin N; Todhunter DA; Panoskaltsis-Mortari A; Vallera DA
Protein Eng; 2002 May; 15(5):419-27. PubMed ID: 12034862
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Anti-Brain Metastasis from Non-Small Cell Lung Cancer of Osimertinib and Doxorubicin Co-Delivery Targeted Nanocarrier.
Wang X; Mao W; Wang Z; Li X; Xiong Y; Lu H; Wang X; Yin H; Cao X; Xin H
Int J Nanomedicine; 2020; 15():5491-5501. PubMed ID: 32848385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
